A Phase II Study of Sacituzumab Tirumotecan in Combination With Furmonertinib in Patients With Non-squamous Non-Small Cell Lung Cancer Who Have Progressed After EGFR-TKI and Platinum-Based Chemotherapy
Clinical trial NCT07548060 · RECRUITING
Trial details
- NCT number
- NCT07548060
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
- Status
- RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2026-02-01
- Primary completion
- 2028-01-22
- Enrollment
- 25
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.